Pfizer and King Pharmaceuticals, Inc. have entered into a definitive merger agreement under which Pfizer will acquire King for $3.6 billion in cash. The transaction, subject to customary closing conditions, is expected to close in late 4Q10 or 1Q11. The acquisition provides an immediate revenue boost from King’s portfolio, which includes a prescription pharmaceutical business focused on new formulations of pain treatments designed to discourage misuse and abuse, as well as the Meridian ...